http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Incidence and case fatality of stroke in Korea, 2011-2020
Jenny Moon(Jenny Moon),Yeeun Seo(Yeeun Seo),Hyeok-Hee Lee(Hyeok-Hee Lee),Hokyou Lee(Hokyou Lee),Fumie Kaneko(Fumie Kaneko ),Sojung Shin(Sojung Shin),Eunji Kim(Eunji Kim),Kyu Sun Yum(Kyu Sun Yum),Young 한국역학회 2024 Epidemiology and Health Vol.46 No.-
Incidence and case fatality of stroke in Korea, 2011-2020
Jenny Moon,Yeeun Seo,Hyeok-Hee Lee,Hokyou Lee,Fumie Kaneko,Sojung Shin,Eunji Kim,Kyu Sun Yum,Young Dae Kim,Jang-Hyun Baek,Hyeon Chang Kim 한국역학회 2024 Epidemiology and Health Vol.46 No.-
OBJECTIVES: Stroke remains the second leading cause of death in Korea. This study was designed to estimate the crude, age-adjusted and age-specific incidence rates, as well as the case fatality rate of stroke, in Korea from 2011 to 2020. METHODS: We utilized data from the National Health Insurance Services from January 1, 2002 to December 31, 2020, to calculate incidence rates and 30-day and 1-year case fatality rates of stroke. Additionally, we determined sex and age-specific incidence rates and computed age-standardized incidence rates by direct standardization to the 2005 population. RESULTS: The crude incidence rate of stroke hovered around 200 (per 100,000 person-years) from 2011 to 2015, then surged to 218.4 in 2019, before marginally declining to 208.0 in 2020. Conversely, the age-standardized incidence rate consistently decreased by 25% between 2011 and 2020. When stratified by sex, the crude incidence rate increased between 2011 and 2019 for both sexes, followed by a decrease in 2020. Age-standardized incidence rates displayed a downward trend throughout the study period for both sexes. Across all age groups, the 30-day and 1-year case fatality rates of stroke consistently decreased from 2011 to 2019, only to increase in 2020. CONCLUSIONS: Despite a decrease in the age-standardized incidence rate, the total number of stroke events in Korea continues to rise due to the rapidly aging population. Moreover, 2020 witnessed a decrease in incidence but an increase in case fatality rates.
Incidence and case fatality of acute myocardial infarction in Korea, 2011-2020
Yeeun Seo(Yeeun Seo),Jenny Moon(Jenny Moon),Hyeok-Hee Lee(Hyeok-Hee Lee),Hyeon Chang Kim(Hyeon Chang Kim),Fumie Kaneko(Fumie Kaneko ),Sojung Shin(Sojung Shin),Eunji Kim(Eunji Kim),Jang-Whan Bae(Jang-W 한국역학회 2024 Epidemiology and Health Vol.46 No.-
Incidence and case fatality of acute myocardial infarction in Korea, 2011-2020
Yeeun Seo,Jenny Moon,Hyeok-Hee Lee,Hyeon Chang Kim,Fumie Kaneko,Sojung Shin,Eunji Kim,Jang-Whan Bae,Byeong-Keuk Kim,Seung Jun Lee,Min Kim,Hokyou Lee 한국역학회 2024 Epidemiology and Health Vol.46 No.-
OBJECTIVES: Cardiovascular diseases are a leading cause of mortality worldwide, and acute myocardial infarction (AMI) is particularly fatal condition. We evaluated the incidence and case fatality rates of AMI in Korea from 2011 to 2020. METHODS: We utilized data from the National Health Insurance Services to calculate crude, age-standardized, and age-specific incidence rates, along with 30-day and 1-year case fatality rates, of AMI from 2011 to 2020. Age-standardized incidence rates were determined using direct standardization to the 2005 population. RESULTS: The crude incidence rate of AMI per 100,000 person-years consistently increased from 44.7 in 2011 to 68.3 in 2019, before decreasing slightly to 66.2 in 2020. The age-standardized incidence rate of AMI displayed a 19% rise from 2011 to 2019, followed by a slight decline in 2020. The increasing trend for AMI incidence was more pronounced in males than in females. Both 30-day and 1-year case fatality rates remained stable among younger individuals but showed a decrease among older individuals. There was a minor surge in case fatality in 2020, particularly among recurrent AMI cases. CONCLUSIONS: Over the past decade, the AMI incidence rate in Korea has consistently increased, with a slight downturn in 2020. The case fatality rate has remained relatively stable except for a minor increase in 2020. This study provides data for continuous surveillance, the implementation of targeted interventions, and the advancement of research aimed at AMI in Korea.
Kim Hyeon Chang,Lee Hokyou,Lee Hyeok-Hee,Lee Ga Bin,Kim Eunji,Song Moses,Moon Jenny,Seo Yeeun,Korean Society of Hypertension (KSH)-Hypertension Epidemiology Research Working Group 대한고혈압학회 2023 Clinical Hypertension Vol.29 No.-
Background The Korean Society of Hypertension has published the Korea Hypertension Fact Sheet 2022 to provide an overview of the magnitude and management status of hypertension and their recent trends. Methods The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 1998–2020 Korea National Health and Nutrition Examination Survey and the 2002–2020 National Health Insurance Big Data. Results As of 2020, 29.4% of the adult population aged 20 or older in Korea, about 12.6 million people, have high blood pressure, of which 5.0 million (40%) are 65 years of age or older and 1.2 million (10%) are 80 years of age or older. Among those with hypertension, the awareness rate is 69%, the treatment rate is 65%, and the control rate is 47%. The number of people diagnosed with hypertension increased from 3.0 million in 2002 to 10.5 million in 2020. During the same period, the number of people using antihypertensive medication increased from 2.5 million to 9.9 million, and the number of people adherent to treatment increased from 0.6 million to 7.4 million. Among those treated for hypertension in 2020, 74% used angiotensin blockers, 61% used calcium channel blockers, 24% used diuretics, and 15% used beta blockers. Combination therapy with at least two classes of antihypertensive medication consisted of 60% of all antihypertensive prescriptions. The number of people with hypertension aged 65 or older is increasing very rapidly compared to those aged 20–64. Awareness and treatment rates of hypertension improved rapidly, especially in those aged 65 or older, but the rate of improvement slowed since 2012. Conclusions In Korea, the level of hypertension management is improving, but the absolute number of people with hypertension, especially elderly hypertension, is increasing due to the rapid aging of the population. It is necessary to develop more efficient and target-specific policies to control blood pressure and prevent cardiovascular disease.
Dyslipidemia Fact Sheet in Korea, 2022
Eun-Sun Jin,Jee-Seon Shim,Sung Eun Kim,배재현,강신애,원종철,Shin Min-Jeong,진흥용,Jenny Moon,이호규,김현창,정인경 한국지질동맥경화학회 2023 지질·동맥경화학회지 Vol.12 No.3
Objective: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022. Methods: We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020. Results: In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia (more than one out of three conditions [low-density lipoprotein-cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein-cholesterol (men and women) <40 mg/dL]) was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-high-density lipoprotein-cholesterolemia in women changed from <40 to <50 mg/dL. Conclusion: Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.